Crystal Ball: 2018 Federal Election
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
AAHP Rouses 38,000 Letters to Capitol Hill and Garners Congressional Support
As the result of the AAHP’s first grassroots effort, 38,000 letters from consumers and health care providers poured into offices of U.S. senators and representatives this spring. The letter-writing campaign urged Congressional leaders to ask the U.S. Food and Drug Administration (FDA) to incorporate key elements of the 1988 guidance regulating homeopathic products into the newly proposed…
How Much Can Machine Learning Help Us?
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
AAHP Speaking Tour
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
Legislative Update: Actions Since FDA’s Draft Guidance
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
United States Food and Drug Administration – Good Guidance Practices
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
Steps Toward Building Grassroots Support
December 6, 2017 Since the FDA hearing and the FTC workshop in 2015, the homeopathic industry has received more attention than usual from regulators. While AAHP continually meets with congressional leaders in Washington and works with both agencies, your association is also working to mobilize stakeholders. It’s important for legislators to hear a cry of…
Recall Preparedness
By Mark Land, AAHP president November 20, 2017 Risks associated with the therapeutic use of healthcare products are real. Manufacturers and the U.S. Food and Drug Administration (FDA) balance these risks all of the time when making marketing authorization decisions. These risks can be evaluable or unanticipated. Evaluable risks from the direct chemical, physical, or…
Annual Certification of Drug Product Listings
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
What’s New at FDA?
By Mark Land, AAHP president September 1, 2017 I took a course several years ago titled Regulatory Intelligence. The first thing the professor said was, “This course is not designed to teach you how to spy on your competitors.” Then she gave us links to 15 news feeds from the U.S. Food and Drug Administration…
AAHP monitors and reports on current federal regulations, legislation and government policies that affect the homeopathic community. AAHP is often the first to learn of regulatory changes that have both direct and indirect effects on our industry enabling members to stay ahead of the curve in a rapidly changing healthcare environment.